AI Summary Harvoni (ledipasvir/sofosbuvir) is a once-daily, single-tablet, interferon-free direct-acting antiviral usually taken for 8 to 12 weeks that helps most hepatitis C patients reach sustained virologic response (SVR).
Medically reviewed.
Harvoni (ledipasvir/sofosbuvir) is a prescription fixed-dose combination medicine that belongs to a class of drugs called direct-acting antivirals (DAAs). It is used to treat chronic hepatitis C virus (HCV) infection in adults, typically with HCV genotype 1, 4, 5, or 6. Harvoni combines two antivirals in a single tablet, works without interferon or ribavirin, and helps most patients reach a cure — known as sustained virologic response (SVR). Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Harvoni's role in hepatitis C treatment — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Harvoni fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT HARVONI TREATMENT
Harvoni is a prescription medicine that combines two antiviral drugs — ledipasvir and sofosbuvir — in a single fixed-dose tablet. It belongs to a class of medications called direct-acting antivirals (DAAs), which target multiple steps in the hepatitis C virus (HCV) life cycle to eliminate the infection.
Unlike older interferon-based regimens, Harvoni is interferon-free and ribavirin-free, and combines two antivirals into one simplified single-tablet regimen. Ledipasvir inhibits the HCV NS5A protein, blocking viral replication and assembly, while sofosbuvir inhibits the NS5B RNA polymerase, preventing viral RNA replication. Together, they stop viral replication at multiple stages, reducing the HCV viral load to undetectable levels.
Harvoni is typically prescribed for adults with chronic hepatitis C, most often HCV genotype 1, 4, 5, or 6. It is used as a time-limited antiviral therapy alongside regular monitoring by your healthcare provider, such as HCV RNA levels and Liver Function Tests (LFTs).
WHO HARVONI MAY BE SUITABLE FOR
Eligibility for Harvoni depends on your HCV diagnosis, genotype, and individual health needs. Your healthcare provider may prescribe Harvoni if you have chronic hepatitis C infection requiring combination antiviral therapy, and you have HCV genotype 1, 4, 5, or 6, depending on clinical guidelines. Harvoni may also be a good fit if you need an interferon-free, ribavirin-free treatment option, prefer a simplified single-tablet regimen, or are eligible for high cure-rate DAA therapy.
Your medical history, HCV genotype, prior treatment history, presence of cirrhosis, current health status, and other medications all factor into whether Harvoni is an appropriate option for you.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Harvoni. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition and treatment goals.
ELIGIBILITY OVERVIEW
Harvoni may be considered for adults with the following conditions or treatment goals:
Before recommending Harvoni, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW HARVONI CAN HELP YOUR LIVER
Harvoni combines two direct-acting antivirals that target the hepatitis C virus at different points in its life cycle. Ledipasvir inhibits the HCV NS5A protein, blocking viral replication and assembly. Sofosbuvir inhibits the NS5B RNA polymerase, preventing viral RNA replication. Together, they stop viral replication at multiple stages.
By blocking these steps, Harvoni reduces the HCV viral load to undetectable levels. For most patients, this leads to a sustained virologic response (SVR) — the medical term for a hepatitis C cure, meaning the virus remains undetectable in the blood months after treatment ends.
For patients with chronic hepatitis C, this combination antiviral effect supports the treatment goal of clearing the virus in a fixed, time-limited course. Harvoni is typically paired with regular monitoring, such as HCV RNA levels and Liver Function Tests (LFTs), to track response throughout treatment.
LIVER BENEFITS
Ledipasvir inhibits the HCV NS5A protein, blocking the steps the virus needs to replicate and assemble new viral particles.
Sofosbuvir inhibits the NS5B RNA polymerase, an enzyme the virus needs to copy its RNA, preventing viral RNA replication.
By acting at multiple stages of the viral life cycle together, ledipasvir and sofosbuvir reduce the HCV viral load to undetectable levels.
For most patients completing treatment, Harvoni helps achieve sustained virologic response (SVR) — the cure of hepatitis C infection.
Harvoni works by stopping HCV replication at two different points in the viral life cycle, helping most patients reach sustained virologic response, or cure. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Harvoni is supplied as a fixed-dose combination tablet. Take it exactly as prescribed, and check with your pharmacist if you have any questions about your specific tablet.
The usual dose is 90 mg ledipasvir / 400 mg sofosbuvir, taken as one tablet once daily. Your healthcare provider determines the right dose for you.
Harvoni is a once-daily oral tablet — it is not an injection or infusion. Take it with or without food, at the same time each day. Always use it exactly as your healthcare provider directs.
Harvoni is used as a time-limited antiviral therapy, typically for 8 to 12 weeks, though duration may extend to 24 weeks in selected patients depending on prior treatment history, HCV genotype, and presence of cirrhosis.
Store Harvoni tablets at room temperature, away from moisture and heat.
Your healthcare provider will regularly monitor HCV RNA levels and liver function tests to track how well the medication is working. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Harvoni (ledipasvir/sofosbuvir) may support people with chronic hepatitis C by combining two direct-acting antivirals in one tablet to stop viral replication at multiple stages. For most patients, this leads to sustained virologic response (SVR), the medical term for a hepatitis C cure. Harvoni is interferon-free and ribavirin-free, offering better tolerability compared to older therapies, and its once-daily, single-tablet regimen makes treatment simple to follow. The extent of benefit and treatment duration varies from person to person, depending on HCV genotype, prior treatment history, presence of cirrhosis, and how the body responds to therapy.
As with any medication, Harvoni may cause side effects, most commonly mild and manageable symptoms such as fatigue, headache, or nausea. Your healthcare provider will monitor your HCV RNA levels and liver function throughout treatment and assess whether Harvoni remains a suitable option for you.
BENEFITS
Harvoni combines ledipasvir and sofosbuvir in a single tablet, simplifying treatment compared to regimens that require multiple pills.
Harvoni helps most patients achieve sustained virologic response (SVR) in most patients — the cure of hepatitis C infection.
Harvoni is taken once a day, offering a simple and easy-to-follow dosing schedule.
Harvoni does not require interferon, offering better tolerability compared to older hepatitis C therapies.
These effects are often mild and may improve as your body adjusts to treatment. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support, including HCV RNA and liver function monitoring, to ensure safe use.
SUPPORTING YOUR RESULTS
Harvoni works best with liver-supportive lifestyle measures such as avoiding alcohol, maintaining a balanced diet, staying hydrated, and managing other liver-related conditions. Patients should also avoid behaviors that increase the risk of reinfection after cure.
These habits can support your overall liver health during treatment and help protect your results once you reach sustained virologic response (SVR).
Areas that may support treatment:
COMMON QUESTIONS
Harvoni treats chronic hepatitis C virus (HCV) infection in adults. It is most often prescribed for people with HCV genotype 1, 4, 5, or 6, depending on clinical guidelines. It does not treat other liver diseases. If you have another liver condition alongside hepatitis C, your healthcare provider will address each condition as part of your overall care plan.
Harvoni combines two antivirals that block the virus at different steps. Ledipasvir inhibits the HCV NS5A protein, which the virus needs to replicate and assemble. Sofosbuvir inhibits the NS5B RNA polymerase, which the virus needs to copy its RNA. Together they reduce the amount of virus in your blood to undetectable levels.
Most people take Harvoni for 8 to 12 weeks. Your healthcare provider may extend treatment to 24 weeks in selected patients. The length depends on your prior treatment history, your HCV genotype, and whether you have cirrhosis. Harvoni is a time-limited therapy, so it has a planned end date rather than being taken indefinitely.
Take one tablet by mouth once a day, with or without food, at the same time each day. The usual dose is 90 mg ledipasvir and 400 mg sofosbuvir in a single fixed-dose tablet. Your healthcare provider determines the right dose for you, so take it exactly as prescribed. Store the tablets at room temperature, away from moisture and heat.
Sustained virologic response (SVR) is the medical term for a hepatitis C cure. It means the virus stays undetectable in your blood months after you finish treatment. SVR is the main goal of Harvoni therapy, and the patient guide reports that Harvoni helps most patients reach it. Your provider confirms it with blood tests.
The most common side effects are fatigue, headache, nausea, diarrhea, and insomnia. These are often mild, and Harvoni is generally better tolerated than older, interferon-based therapies. Tell your healthcare provider about any side effects or unusual symptoms, especially if they are severe or do not improve, so they can decide how to manage them.
Yes, reinfection is possible, so protecting your liver after treatment still matters. Your healthcare provider will keep monitoring your HCV RNA levels and liver function tests to track your response. To support your results, avoid alcohol, eat a balanced diet, stay hydrated, manage other liver-related conditions, and avoid behaviors that raise the risk of reinfection.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
